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Triple-negative breast cancer (TNBC) is associated with a higher incidence of recurrence and distant metastasis and
a poor prognosis, whereas effective treatment strategies remain to be established. Finding an effective treatment
for TNBC has become imperative. We examined the effect of the combination of S-1 (or 5-FU in an in vitro study)
and eribulin in TNBC cell lines. The in vitro effect of the combination was examined in four TNBC cell lines (MDA-MB-231,
MDA-MB-468, BT-549 and MX-1) using a combination index and isobolograms. In addition, we assessed the effect of
the combination in an MDA-MB-231 tumor xenograft model. A synergistic effect was observed in three TNBC cell lines
(MDA-MB-231, MDA-MB-468, and MX-1), and in an in vivo study, the combination of S-1 and eribulin resulted in
significantly higher antitumor effects compared with S-1 or eribulin alone. 5-FU induced epithelial-mesenchymal
transition (EMT) change in the TNCB cell line, as supported by the decreased expression of epithelial marker and
the increased expression of mesenchymal markers. Meanwhile, TGF-beta induced EMT changes in a TNBC cell
line and decreased the sensitivity to 5-FU. This result suggests that 5-FU-induced EMT changes reduce the
sensitivity to 5-FU. In contrast, eribulin induced a mesenchymal-epithelial transition (MET) in a TNBC cell line.
The EMT phenotype induced by 5-FU was also canceled by eribulin. We demonstrate that the combination of
S-1 (5-FU) and eribulin exerts a synergistic effect for TNBC cell lines through MET-induction by eribulin. Therefore, this
combination therapy may be a potential treatment option for TNBC.
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Metastatic breast cancer is a heterogeneous disease in its
biology, clinical behavior, prognosis, and treatment. Whereas
patients with hormone receptor-positive and HER-2-positive
breast cancers have had favorable outcomes with chemo-
therapy and targeted therapies, triple-negative breast cancer
(TNBC) is not sensitive to conventional chemotherapies.
TNBC is a clinical phenotype characterized by a lack of
overexpression or gene amplification of hormone recep-
tors (estrogen receptor [ER] and progesterone receptor
[PR]) and human epidermal growth factor receptor-2
(HER-2). TNBC accounts for between 9% and 16% of all
breast cancers and is associated with a poor prognosis* Correspondence: knishio@med.kindai.ac.jp
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S-1 (Taiho Pharmaceutical Co., Tokyo, Japan) is an oral
fluoropyrimidine derivative composed of 1-(2-tetrahydro-
furyl)-5-fluorouracil (tegafur, a prodrug of 5-flurouracil
[5-FU]), combined with two modulators of 5-FU activity,
5-chloro-2, 4-dihydroxypyrimidine (gimeracil) and potas-
sium oxonate (oteracil) (Shirasaka et al. 1996). S-1 has
been widely approved for gastric cancer treatment in
many countries in Asia and Europe (Satoh & Sakata
2012) and for several other cancers in Japan (Shirasaka
2009). In a phase II clinical study, S-1 monotherapy was
demonstrated to have high antitumor activity with toler-
ated toxicities in metastatic breast cancer (Saek et al.
2004). Moreover, it was reported at the Annual Meeting
of The Japanese Breast Cancer Society (Futsuhara 2012)
that an additional treatment with S-1 for 12 months wasis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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cycline or taxane.
Eribulin mesylate (eribulin; Eisai Co., Tokyo, Japan) is a
non-taxane, microtubule dynamics inhibitor with a novel
mechanism of the action, which induces irreversible mi-
totic block at the G2-M phase and apoptosis (Kuznetsov
et al. 2004; Towle et al. 2001; Jordan et al. 2005; Okouneva
et al. 2008; Smith et al. 2010; Towle et al. 2011). In a ran-
domized clinical phase III study (Eisai Metastatic Breast
Cancer Study Assessing Physician’s Choice Versus E7389,
EMBRACE) involving patients with heavily pre-treated lo-
cally recurrent or metastatic breast cancer, eribulin was
compared with the treatment of physician’s choice (TPC).
Patients who received eribulin exhibited a significant im-
provement in median overall survival compared with TPC
(Cortes et al. 2011). Recently, sub-group analysis from
phase III clinical trial demonstrated that women with
TNBC had significant response to treatment with eribu-
lin versus capecitabine, with a median overall survival of
14.4 months with eribulin, compared with 9.4 months
with capecitabine (Kaufman et al. 2012).
Because a monotherapy of S-1 or eribulin has shown
promising activity in TNBC and eribulin have a manage-
able toxicity and a modest incidence of neuropathy, which
appears to be lower than with other microtubule inhibitor
agents, the combination of S-1 and eribulin is a hopeful
combination regimen for breast cancer including TNBC.
Phase I trial of S-1 and eribulin combination therapy for
advanced or recurrent breast cancer pretreated by anthra-
cycline and taxane is being executed in Kinki University
Hospital. However, no preclinical studies of this combin-
ation have been performed. In this study, we investigated
the combination effect of S-1 (5-FU) and eribulin on
TNBC cell lines both in vitro and in vivo. In addition, we
investigated the mechanisms of the synergistic effects of
S-1 (5-FU) and eribulin.
Methods
Cell lines
This study was performed using four TNBC cell lines
(MDA-MB-231, MDA-MB-468, BT-549, and MX-1) and
two non-TNBC cell lines (MCF-7, T47D). These cells
were obtained from ATCC (Rockville, MD, USA) or CLS
(Eppelheim, Germany) and were maintained in RPMI-1640
medium (Sigma-Aldrich, St. Louis, MO, USA) supple-
mented with 10% fetal bovine serum (Gibco BRL, Grand
Island, NY, USA) and cultured under a humidified atmos-
phere of 5% CO2 at 37°C, passaged every 3–4 days.
Compounds
S-1 was prepared by mixing tegafur, gimeracil, and oter-
acil potassium (TCI, Tokyo, Japan) at a molar ratio of
1:0.4:1 in 0.5% HPMC. 5-FU was obtained from Sigma-
Aldrich for the in vitro study and eribulin was providedby Eisai Co. These agents were dissolved in dimethyl
sulfoxide (DMSO).
In vitro growth inhibition assay
Cell growth was assessed using a standard 3-(4, 5-
dimenthyl-thiazoyl-2-yl) 2, 5-diphenyltetrazolium bromide
(MTT) assay and a previously described method (Tanaka
et al. 2009). Briefly, cells were seeded into a 96-well plate
and were cultured for 24 h before exposure to the com-
pounds. The cells were incubated for 72 h at 37°C with
various concentrations of 5-FU and eribulin. The experi-
ment was performed in triplicate.
Combination effect of 5-FU and eribulin in vitro
To evaluate the combination effect, the normalized ED50
isobologram was plotted using an MTT assay. An isobolo-
gram analysis is a frequently used method for analyzing
the effects of multiple drugs (Steel & Peckham 1979; Kano
et al. 1988). In addition, the combination index (CI) (Chou
& Talalay 1984) was calculated for each combination ratio
using the following formula:




where (Da)1 and (Da)2 are the concentrations required
for single agents to achieve a% drug effect (in this ex-
periment, a = 50) and (D)1 and (D)2 are the concentra-
tions of 5-FU and eribulin used in combination to
achieve the same effect. In a normalized isobologram,
the diagonal line represents the additive effect. Experi-
mental data points, represented by dots located below,
on, or above the line, indicate synergism, additively, and
antagonism, respectively. The CI equation determines
the additive effect of drug combinations, with synergism
being defined as greater than the expected additive effect
and antagonism being defined as less than the expected
additive effect. Thus, CI values <1, 1, and >1 indicate
synergism, additively and antagonism, respectively.
Real-time reverse-transcription (RT) PCR
Total RNA was converted to cDNA using a GeneAmp®
RNA-PCR kit (Applied Biosystems, CA, USA). The cDNAs
were used for PCR analysis using oligonucleotide primers
specific for E-cadherin (forward 5’-TTAAACTCCTGGCC
TCAAGCAATC-3’ and reverse 5’-TCCTATCTTGGGCA
AAGCAACTG-3’) N-cadherin (forward 5’-CGAATGGAT
GAAAAGACCCATCC-3’ and reverse 5’-GGAGCCACTG
CCTTCATCGTCAA-3’) vimentin (forward 5’-TGAGTAC
CGGAGACAGGTGCAG-3’ and reverse 5’-TAGCAGCT
TCAACGGCAAAGTTC-3’) and Snail2 (forward 5’-ATGC
ATATTCGGACCCACACATTAC-3’ and reverse 5’-AGA
TTTGACCTGTCTGCAAATGCTC-3’). The PCR was
performed using Thermal Cycler Dice (TaKaRa, Otsu,
Table 1 IC50 value of 5-FU and eribulin
Cell lines 5-FU (μM) Eribulin (nM)
TNBC MDA-MB-231 13.0 ± 2.0 1.2 ± 0.3
MDA-MB-468 8.6 ± 2.5 0.7 ± 0.2
BT-549 5.3 ± 0.5 1.6 ± 0.2
MX-1 92.4 ± 3.7 4.3 ± 0.6
Non-TNBC MCF-7 2.3 ± 0.4 0.4 ± 0.0
T47D 5.1 ± 0.4 2.6 ± 1.1
Growth inhibitory effect of single agent 5-FU or eribulin in four TNBC cell lines
and two non-TNBC cell lines. MTT assays were performed. The IC50 values
of each agent were shown at 72 hours after exposure. Each value is the
average ± SD of three independent experiments.
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50 cycles of 95°C for 5 s, and 60°C for 10 s. The primers
were purchased from Sigma-Aldrich or TaKaRa and were
used with SYBR® Premix Ex Taq (TaKaRa). GAPDH was
used as an internal control to normalize and compare
each sample.
Immunoblotting
Immunoblot analysis was performed as described previ-
ously (Maegawa et al. 2009). Cells were washed twice
with phosphate-buffered saline (PBS) and lysed by incu-
bating in Lysis A buffer containing 1% Triton X-100,
20 mM Tris–HCl (pH7.0), 5 mM EDTA, 50 mM sodium
chloride, 10 mM sodiumpyrophosphate, 50 mM sodium
fluoride, 1 mM sodium orthovanadate, a protease inhibi-
tor cocktail tablet (Complete, Mini; Roche Diagnostics,
Basel, Switzerland) and phosphatase inhibitor cocktail
(Sigma-Aldrich). Proteins were resolved using SDS-PAGE
and were transferred to a PVDF membrane (Immobilon;
Millipore, Billerica, MA, USA). After blocking with
Tris-buffered saline (TBS) containing 0.02% Tween 20
and 5% nonfat milk, the strips of membrane were ex-
posed to anti-E-cadherin antibody, anti-N-cadherin
antibody, anti-vimentin antibody, anti-Snail2 antibody,
or anti-β-actin antibody. They were incubated with
HRP-conjugated anti-rabbit IgG antibody and the pro-
teins were visualized using an ECL Western Blotting
Detection System (GE Healthcare, Buckinghamshire,
UK). The antibodies were all purchased from Cell Sig-
naling (Beverly, MA, USA).
Immunofluorescence staining
Immunofluorescence staining of cells were performed as
described previously (Tamura et al. 2010) with minor
modifications. Cells were seeded onto cover slips in 6-well
plates and exposed to 5-FU, eribulin, or TGF-β. After ex-
posure, the cells were washed twice with PBS, then fixed
with 4% paraformaldehyde for 20 min. The fixed cells
were washed three times with PBS and were subsequently
incubated for 1 hour with 1.5% bovine serum albumin.
They were then incubated over night with anti-E-cadherin
or anti-vimentin antibodies at 4°C, followed by incubation
with Alexa Fluor 546 anti-rabbit IgG antibody (Molecular
Probes, Eugene, OR, USA) for 30 min. Finally, the cells
were treated with DAPI (6-diamidino-2-phenylindole) to
stain the nucleus and the stained cells were observed using
fluorescence microscopy (IX71; Olympus, Tokyo, Japan).
In vivo growth inhibition assay
Female BALB/c-nu/nu mice (5 weeks old; CLEA Japan
Inc., Tokyo, Japan) were used for the in vivo studies and
were cared for in accordance with the recommendations
for the handling of laboratory animals for biomedical re-
search compiled by the Committee on Safety and EthicalHandling Regulations for Laboratory Animal Experiments,
Kinki University. MDA-MB-231 cells (4 × 106 viable cells)
in PBS containing 50% Matrigel were injected subcutane-
ously into each mouse. Thirty days following the inocula-
tion of the cells, the mice were divided randomly into 4
groups (control, S-1, eribulin, and S-1 plus eribulin; n = 3
each), and treatment was initiated. S-1 was administered
orally on days 1 to 16, and eribulin dissolved in saline con-
taining 2.5% DMSO was injected intravenously on days 1,
5, 9, and 13. The doses of S-1 and eribulin were 8.3 mg/kg
and 0.1 mg/kg, respectively. The tumor volumes were esti-
mated using the formula [(width)2 × length]/2 (mm3). To
evaluate the anti-tumor effects of the S-1, eribulin, and a
combination of S-1 and eribulin, the tumor sizes and body
weights were measured twice per week. Antitumor effects
were expressed as % T/C (treated versus control), dividing
the tumor volumes from the treatment groups by those of
the control groups and multiplying by 100.
Hematoxylin-Eosin (HE) staining and immunohistochemical
(IHC) analysis
Formalin-fixed tumors were paraffin-embedded. 4 μm sec-
tions were used for HE staining, and IHC using antibodies
against E-cadherin (1:100) and to vimentin (1:100). The
methods used in this section have been described previ-
ously (Tamura et al. 2013).
Statistical analysis
The statistical analyses were performed using Microsoft
Excel (Microsoft) to calculate the SD and to test for statis-
tically significant differences between the samples using a
Student's t test. A P value of <0.05 was considered statisti-
cally significant.
Results
Cellular sensitivity of TNBC cell lines to 5-FU and eribulin
The growth inhibitory effects of 5-FU and eribulin on
TNBC cell lines and non-TNBC cell lines are examined
using an MTT assay. The IC50 values of 5-FU and eribu-
lin for the cell lines fell within the ranges of 2.3-13.0 μM
and 0.4-4.3 nM, respectively. There was no difference in
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non-TNBC cell line, except for the MX-1 cells (Table 1).
The MX-1 cells had a higher resistance to 5-FU (92.4 ±
3.7 μM) than the other cell lines.
In vitro combination effect of 5-FU and eribulin on TNBC
cell lines
To evaluate the potential combined effect of 5-FU and eri-
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Figure 1 Combination effect of 5-FU and eribulin in four TNBC cell lin
TNBC cell lines after 72 hours exposure. (b) Normalized isobologram analys
points, represented by dots located below, on, or above this line indicate s
below and to the left of the line represent synergism.CI values were determined using an MTT assay. A syner-
gistic interaction between 5-FU and eribulin was observed
in the TNBC cell lines (MDA-MB-231, MDA-MB-468,
and MX-1) (Figure 1a). In addition, the CI values were sig-
nificantly <1 and isobolograms clearly revealed synergy at
all explored concentrations (Table 2 and Figure 1b). An
additive effect was observed in the BT-549 cell line. Thus,
we found a synergistic or additive effect for the combin-




































































es. (a) Growth inhibitory effect of combination of 5-FU and eribulin in
is. The diagonal line represents the additive effect. Experimental data
ynergism, additively, and antagonism, respectively. Points located
Table 2 CI value of combination of 5-FU and eribulin
Combination ratio Cell lines
5-FU (μM):
eribulin (nM)
MDA-MB-231 MDA-MB-468 MX-1 BT-549
1 : 0.003 0.95 1.12
1 : 0.01 0.61 0.81 0.46 1.27
1 : 0.03 0.58 0.73 0.27 1.08
1 : 0.1 0.60 0.63 0.44 1.08
1 : 0.3 0.63 0.64 0.60 1.18
1 : 1 0.57 0.61 0.73 1.09
1 : 3 0.61 0.70
The CI values were calculated in each combination ratio. The CI values of <1,
1, or >1 indicate synergism, additively, and antagonism, respectively.
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to 5-FU
We analyzed the mechanisms of the synergistic inter-
action between 5-FU and eribulin. Several reports have
demonstrated that established 5-FU-resistant cell lines
exhibit EMT changes (Chung et al. 2000; Zhang et al.
2012), we examined focusing on EMT. First, we exam-
ined whether EMT changes in MDA-MB-231 cells might
reduce the cellular sensitivity to 5-FU. When MDA-MB-
231 cells were exposed to TGF-β (2.5 ng/mL) for 5 days,
an EMT-like morphological change was observed
(Figure 2a). The decreased expression of E-cadherin and
the increased expression of N-cadherin, vimentin anda b
d e
Figure 2 TGF-β induces EMT in MDA-MB-231 cells after 5 days of exp
changes of MDA-MB-231 cells after exposure to 2.5 ng/mL of TGF-β. (b) Th
Snail2 were determined using real-time RT-PCR. GAPDH was used to norm
of three independent experiments. *P < 0.05 versus control. (c) Western blo
was used as an internal control. (d) Immunofluorescence staining of E-cadher
growth inhibition curves of 5-FU in MDA-MB-231 cells with or without TGF-βSnail2 were observed at the mRNA and protein expres-
sion levels (Figure 2b and c). Immunofluorescence stain-
ing confirmed these changes in E-cadherin and vimentin
(Figure 2d). Figure 2e shows the cellular sensitivity of
MDA-MB-231 cells to 5-FU under this condition. The
cells that were exposed to TGF-β had an approximately
3-fold higher resistance to 5-FU, with IC50 values of
44.7 ± 5.8 μM, compared with that of cells without TGF-β
exposure (14.8 ± 1.0 μM). These results showed the EMT
changes in MDA-MB-231 cells reduced cellular sensitivity
to 5-FU.5-FU induces epithelial-mesenchymal transition (EMT)
When MDA-MB-231 cells were treated with 5-FU
(1–10 μM), we observed that MDA-MB-231 cells dis-
played EMT-like changes in cell morphology, including
the elongation of the cell shape and cell scattering,
which are characteristic features of cells undergoing EMT
(Figure 3a). Real-time RT-PCR and western blotting dem-
onstrated the decreased of an epithelial marker (E-cadherin),
whereas the expressions of mesenchymal markers (N-cad-
herin and vimentin) and Snail2, which are transcriptional
repressors of E-cadherin, were increased after 5 days of 5-
FU exposure in dose-dependent manners (Figure 3b
and c). The decreased expression of E-cadherin and the
increased expression of vimentin were also confirmed
using immunofluorescence staining (Figure 3d). Thesec
osure and reduced the sensitivity to 5-FU. (a) Morphological
e mRNA expression levels of E-cadherin, N-cadherin, vimentin and
alize the expression levels. The data shown represent the average ± SD
tting analysis for E-cadherin, N-cadherin, vimentin, and Snail2. β-actin
in and vimentin. The nucleus (blue) was stained with DAPI. (e) Cellular
exposure.
Figure 3 5-FU induces EMT in MDA-MB-231 cells after 5 days of exposure. (a) Morphological changes in MDA-MB-231 cells after exposure
to 1, 3, or 10 μM of 5-FU. (b) The mRNA expression levels of E-cadherin, N-cadherin, vimentin and Snail2 were determined using real-time
RT-PCR. GAPDH was used to normalize the expression levels. The data shown represent the average ± SD of three independent experiments.
*P < 0.05 versus control. (c) Western blotting analysis for E-cadherin, N-cadherin, vimentin, and Snail2. β-actin was used as an internal control.
(d) Immunofluorescence staining of E-cadherin and vimentin. The nucleus (blue) was stained with DAPI.
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MDA-MB-231 cells and the EMT changes might reduce
the sensitivity to 5-FU.
Eribulin induces mesenchymal-epithelial transition (MET)
In contrast, MX-1 cells, which exhibit mesenchymal fea-
tures, displayed MET morphologically changes including a
cobblestone-like appearance and tight cell–cell junctions,
the reverse process of EMT, after 8 days exposure to eribu-
lin (0.3-3 nM) (Figure 4a). In agreement with these observa-
tions, the increased expression of E-cadherin and the
decreased expression of N-cadherin and vimentin in associ-
ation with decreased expression of Snail2 were detected in
dose-dependent manners (Figure 4b and c). Immunofluor-
escence staining also confirmed the increased expression of
E-cadherin and the decreased expression of vimentin
(Figure 4d). To examine whether eribulin cancels 5-FU-
induced EMT changes in MDA-MB-231 cells, the cells
were pre-exposed to 5-FU for 5 days, followed by expos-
ure to eribulin. Morphological changes from fibroblast-
like shapes to a cobblestone appearance were observedafter eribulin-exposure (0.3-3 nM) for 4 days (Figure 5a).
The increased expression of E-cadherin and the de-
creased expression of N-cadherin, vimentin and Snail2
were also observed in dose-dependent manners, as de-
tected using real-time RT-PCR, western blotting, and
immunofluorescence staining (Figures 5b-d). Thus, the
5-FU induced EMT phenotype in MDA-MB-231 cells
was also canceled by eribulin. These results suggested
the action of MET induction by eribulin reduced the 5-
FU resistance.
Combination effect of S-1 and eribulin in an MDA-MB-231
tumor xenograft model
To assess the combination effect of S-1 and eribulin
in vivo, we examined the antitumor activity of this com-
bination in an MDA-MB-231 tumor xenograft model.
Mice bearing MDA-MB-231 tumors were prepared and
treated with S-1 (days 1–16; p.o., 8.3 mg/kg), eribulin
(Q4D × 4; i.v., 0.1 mg/kg), or S-1 plus eribulin. The
mean tumor volumes (mm3) on day 36 following the




Figure 4 Eribulin induces MET in MX-1 cells after 8 days of exposure. (a) Morphological changes of MX-1 cells after exposure to 1, 3, or 10 nM of
eribulin. (b) The mRNA expression levels of E-cadherin, N-cadherin, vimentin and Snail2 were determined using real time RT-PCR. GAPDH was used to
normalize the expression levels. The data shown represent the average ± SD of three independent experiments. *P < 0.05 versus control. (c) Western
blotting analysis for E-cadherin, N-cadherin, vimentin, and Snail2. β-actin was used as an internal control. (d) Immunofluorescence staining of
E-cadherin (red) and vimentin (red). The nucleus (blue) was stained with DAPI.
Terashima et al. SpringerPlus 2014, 3:417 Page 7 of 11
http://www.springerplus.com/content/3/1/417eribulin, and S-1 plus eribulin) were 1900 ± 473, 1055 ±
197, 900 ± 235, and 199 ± 26, respectively (Figure 6a,
P = 0.01, S-1 monotherapy versus S-1 plus eribulin; P =
0.04, eribulin versus S-1 plus eribulin). S-1 or eribulin
alone inhibited the tumor growth (T/C = 55.5%, 47.4%,
respectively), and a combination of S-1 and eribulin inhib-
ited the tumor growth of MDA-MB-231 xenografts
more intensively (T/C = 10.5%). Body weight loss related
to treatment with S-1 or eribulin was not observed in
any of the groups (Figure 6b). Further, we examined the
MET induction activity of eribulin using a xenograft
model. Immunohistchemical analyses were performed in
above four groups on day 7 following the initial treatment.
As a result, the decreased expression of E-cadherin and
the increased expression of vimentin were observed after
treatment of S-1. In contrast, the increased expression of
E-cadherin and the decreased expression of vimentin were
observed after treatment of combined with eribulin
(Figure 6c). These results were consistent with the in vitro
experiments.Discussion
Patients with advanced or metastatic breast cancer have
limited treatment options. Patients with TNBC can re-
ceive systemic therapy only due to lack of targeted ther-
apies and many patients fail to respond or become
refractory to the treatment. In spite of high response
rate to chemotherapy in the initial treatment, TNBC pa-
tients develop rapid disease progression resulting in a
shorter overall survival compared to ER-positive breast
cancer (Foulkes et al. 2010). Metastatic breast cancer is
an incurable disease and the purpose of chemotherapy is
relieving symptoms and improving quality of life. Al-
though combination chemotherapies such as docetaxel-
capecitabine were demonstrated superior efficacy for
metastatic breast cancer, nonhematologic toxicities were
significantly higher (O'Shaughnessy et al. 2002). Re-
cently, in studies with selected patients referred for
BRCA genetic testing the frequency of TNBC has been
reported to be 57% in BRCA1 mutation carriers, and




Figure 5 Eribulin induces MET in MDA-MB-231 cells in which EMT changes have been induced by 5-FU. (a) Morphological changes of
MDA-MB-231 cells after 5 days of 5-FU treatment and 3 additional days of eribulin treatment. (b) The mRNA expression levels of E-cadherin,
N-cadherin, vimentin and Snail2 were determined using real time RT-PCR. GAPDH was used to normalize the expression levels. The data shown
represent the average ± SD of three independent experiments. *P < 0.05 versus control. (c) Western blotting analysis for E-cadherin, N-cadherin,
vimentin, and Snail2. β-actin was used as an internal control. (d) Immunofluorescence staining of E-cadherin (red) and vimentin (red). The nucleus
(blue) was stained with DAPI.
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such as olaparib, which has been shown to be safe and
effective in BRCA-related cancers. However, the benefit
of iniparib in phase II trial was not confirmed in the
subsequent phase III trial (Audeh et al. 2010). Thus,
novel therapies and treatment modalities for TNBC are
necessary.
In this study, we demonstrated that the combination
of 5-FU and eribulin exerted synergistic (3/4) or additive
(1/4) effects against TNBC cell lines in vitro. The syner-
gistic effect of S-1 with eribulin was also demonstrated
in a tumor-bearing model. In the in vivo experiment, we
analyzed the antitumor effects of S-1 and eribulin ac-
cording to the optimal dose and schedule for each drug.
The combination was tolerable and resulted in the remark-
able reduction of tumor growth in mice without remarkable
toxicities including body-weight loss and diarrhea. These
preclinical studies are first reports and these results show
that the combination may be potential therapy for TNBC
patients.EMT has emerged to play important roles in the devel-
opment of the invasive and metastatic potentials of cancer
progression (Hugo et al. 2007; Peinado et al. 2007; Tsuji
et al. 2009). In addition to this action, recent evidence in-
dicates that EMT changes develop a resistance to a several
anti-cancer agents such as EGFR-tyrosine kinase inhibitor,
cisplatin, gemcitabine, and 5-FU (Singh & Settleman 2010;
Thomson et al. 2005; Frederick et al. 2007; Zhuo et al.
2008; Arumugam et al. 2009; Wang et al. 2009). Actually,
MX-1 cells, which assume intense mesenchymal feature,
show low sensitivity to 5-FU and we ascertained that
TGF-β-induced EMT change in TNBC cell line showed
remarkably resistant to 5-FU. Furthermore, 5-FU directly
induced EMT change in TNBC cells, and this action of
5-FU is likely to be associated with acquired resistance. In
contrast, the present study has shown that eribulin in-
duced MET, and current preclinical studies represent that
eribulin reverses EMT and induce MET in TNBC cells
through regulating TGF-β signal pathway, especially
down-regulation of Smad2 and Smad3 phosphorylation
a b
c
Figure 6 Combination effects of S-1 and eribulin in an in vivo xenograft model. (a) The tumor volumes of the four groups are plotted from
day 30 until day 66 after the inoculation of MDA-MB-231 cells. The data shown represent the average values (bars, SD). *P < 0.05 versus control,
**P < 0.05 versus S-1 or eribulin alone. (b) Body weight loss in mice. (c) HE staining assay and IHC assays using mouse tumor samples. Tumors
were collected after 7 days of treatment and the prepared tissue slides were analyzed with HE staining and IHC using anti-E-cadherin and
anti-vimentin antibodies.
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report and eribulin moreover reversed the 5-FU-induced
EMT in TNBC cells. These results were conformed both
of in vitro and in vivo experiments. The action of eribulin
on MET may improve the 5-FU resistance, resulting in
produced a synergistic effect. Because of evidence of an
association between EMT change and resistance to several
other anti-cancer agents, these actions of eribulin provide
a rationale for the combination of these agents. Moreover,
a previous report demonstrated that a portion of TNBCtumors among clinical samples exhibit EMT changes and
these subsets are significantly associated with a high histo-
logical grade (Jeong et al. 2012). Therefore, our combin-
ation treatment is expected to be a useful treatment
strategy for EMT-positive TNBC.
In conclusion, we showed that the combination of S-1
(5-FU) and eribulin exerts a synergistic anti-tumor effect
against TNBC cell lines in vitro and in vivo through the
MET induction by eribulin. This combination may be
beneficial to TNBC treatment, and the present evidence
Terashima et al. SpringerPlus 2014, 3:417 Page 10 of 11
http://www.springerplus.com/content/3/1/417provides a good rationale to clinical studies for meta-
static breast cancer patients. Currently, we are conduct-
ing a clinical study of S-1 and eribulin combination for
metastatic breast cancer and clinical benefit of this regimen
is being evaluated.
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